RecruitingNCT05586282
Role of Candidate Proteins in Capillary Leakage During Acute Circulatory Failure
Sponsor
Assistance Publique - Hôpitaux de Paris
Enrollment
380 participants
Start Date
Mar 20, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
* Testing the association between circulating candidate proteins and the level of vascular leakage for three distinct forms of circulatory failure: cardiogenic shock, septic shock, and post-resuscitation syndrome. * Describing immuno-inflammatory profiles associated with massive vascular leakage during those three forms of circulatory failure in humans
Eligibility
Min Age: 18 Years
Inclusion Criteria19
- Informed consent from patient or a legal representative/family member/close relative. The patient will be asked to give his/her consent for the continuation of the trial when his/her condition will allow.
- Affiliation to social security (AME excluded)
- Patient with one of the circulatory failures described below:
- septic shock
- cardiogenic shock
- post-resuscitation syndrome
- Cardiogenic shock:
- Need for a catecholamine support to maintain mean arterial pressure\>65 mmHg, AND
- Cardiac index \<2 L/min/m2 or left ventricular ejection fraction (LVEF)\<35%, AND
- Lactate \>2.0 mmol/l
- Post-resuscitation syndrome:
- Cardiac arrest (absence of spontaneous respiration, palpable heartbeat, and responsiveness to stimuli\> 1 min) with a compatible electrocardiogram (asystole/pulseless electrical activity/ventricular tachycardia), AND
- Need for a catecholamine support to maintain mean arterial pressure\>65 mmHg, AND
- Lactate \>2.0 mmol/l
- Septic shock:
- Suspected or proven bacterial infection
- Need for a vasopressor support to maintain mean arterial pressure\>65 mmHg
- Lactate \>2.0 mmol/l
- Cardiac index\>3L/min/m2 or LVEF\>40%
Exclusion Criteria3
- Onset of shock (catecholamine infusion) \>12 hours prior to inclusion
- Age \<18 year old
- Pregnancy
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05586282
Related Trials
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
NCT044194801 location
Magenta Elevate™ Clinical Feasibility Study in Cardiogenic Shock
NCT072939235 locations
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
NCT060800745 locations
Rate, Rhythm or Risk Control for New-onset Supraventricular Arrhythmia During Septic Shock: a Randomized Controlled Trial
NCT048448011 location
Echocardiography-guided Cirrhosis and Liver Failure-Intensive Care Protocol Sepsis
NCT072866431 location